- Home
- LYFT vs ZTS Comparison
LYFT vs ZTS Comparison
Compare LYFT & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | ZTS |
|---|---|---|
| Founded | 2007 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 66.2B |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LYFT | ZTS |
|---|---|---|
| Price | $20.28 | $118.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 32 | 11 |
| Target Price | $22.68 | ★ $174.60 |
| AVG Volume (30 Days) | ★ 13.4M | 5.0M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 1.69% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | 0.36 | ★ 5.94 |
| Revenue | $6,273,827,000.00 | ★ $9,397,000,000.00 |
| Revenue This Year | $14.36 | $3.11 |
| Revenue Next Year | $14.15 | $5.14 |
| P/E Ratio | $56.14 | ★ $19.99 |
| Revenue Growth | ★ 14.90 | 2.68 |
| 52 Week Low | $9.66 | $115.25 |
| 52 Week High | $25.54 | $181.85 |
Technical Indicators
Market Signals| Indicator | LYFT | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 38.87 |
| Support Level | $19.78 | $115.59 |
| Resistance Level | $23.33 | $129.58 |
| Average True Range (ATR) | 0.89 | 3.06 |
| MACD | -0.16 | 0.17 |
| Stochastic Oscillator | 25.75 | 23.09 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.